Doctor Jeanmarie Guenot is the President and Chief Executive Officer of Amphivena Therapeutics Incorporated established in July 2013. Guenot has spent over 20 years in the pharmaceutical and biotechnology industry. In the past, she has been involved in all aspects of cancer research with multiple public and private companies including research and development, corporate and commercial development, business development, project and alliance management, and venture capital. Media outlets that have highlighted a few of Guenot’s accomplishments include Market Wired, Yahoo, Biospace.com, and Reuters.
Doctor Guenot started with Atlas Venture managing venture capital investments, and worked as a scientist with preclinical research and development at Hoffman LaRoache where drugs were developed to assist in eliminating metabolic diseases. Prior to her move to Amphivena Therapeutics, Guenot built and ran SKS Ocular which is an ophthalmic incubator company focusing on dry AMD, sustained release ocular drug delivery technologies for glaucoma, macular degeneration and ocular inflammation. Today, Amphivena Therapeutics develops cancer immunotherapies.
A recent accomplish includes the Food and Drug Administration (FDA) accepting an investigational new drug application for AMV564 which is an Amphivena Therapeutics proprietary T-cell redirecting bispecific CD33/CD3 antibody that helps recruit T-cells to rid of cancer cells. By doing so, doctors will now have at their disposal a therapeutic option for AML patients. Guenot and Amphivena Therapeutics look to stop blood cancers with therapies that use the patient’s immune system to destroy the tumor cells.
Amphivena Therapeutics has joined forces with multiple alliances and together is using their experience and resources in the industry to focus on how best to come up with therapy options for patients. Statistically, there is an expectation that over 19 million people will be diagnosed with cancer by the year 2024. This amounts to 39.6% of the world’s population of men and women. The work that Doctor Jeanmarie Guenot and her team members are completing will slow down cancer in the short term and hopefully rid of the disease altogether in the future.
Read more on her website here: http://jeanmarieguenot.com/